bluebird bio, Inc. (NASDAQ:BLUE) Given Average Rating of “Hold” by Analysts

bluebird bio, Inc. (NASDAQ:BLUE) has earned an average rating of “Hold” from the eight brokerages that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $44.60.

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. Barclays reduced their price objective on bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. Baird R W cut bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. Wall Street Zen began coverage on bluebird bio in a research note on Thursday, May 15th. They set a “sell” rating on the stock. Finally, Wells Fargo & Company reduced their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, February 24th.

Institutional Investors Weigh In On bluebird bio

Hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its stake in bluebird bio by 12.7% in the first quarter. Bank of New York Mellon Corp now owns 32,759 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 3,686 shares during the last quarter. Regeneron Pharmaceuticals Inc. bought a new stake in bluebird bio in the fourth quarter valued at $175,000. Murchinson Ltd. bought a new stake in bluebird bio in the first quarter valued at $254,000. Goldman Sachs Group Inc. lifted its stake in bluebird bio by 4.7% in the first quarter. Goldman Sachs Group Inc. now owns 64,950 shares of the biotechnology company’s stock valued at $317,000 after buying an additional 2,932 shares during the last quarter. Finally, Groupe la Francaise bought a new stake in bluebird bio in the first quarter valued at $679,000. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Price Performance

BLUE stock opened at $4.97 on Wednesday. bluebird bio has a 52-week low of $3.20 and a 52-week high of $28.60. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $48.67 million, a PE ratio of -0.13 and a beta of 0.27. The stock’s 50 day moving average is $4.53 and its two-hundred day moving average is $5.97.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.